Cyonics Cyto Solutions Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 389.62%
- Profit Growth 129.11%
- Ebitda 138.46%
- Net Worth 7.09%
- Total Assets 13.23%
About Cyonics Cyto Solutions
Cyonics Cyto Solutions Private Limited (CCSPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 July 2014 and has a history of Ten years and six months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Venkatakanthaiah Yerramalla, Srikanth Boga, and Shivanand Sindol serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74900TG2014PTC094934
-
Company No.
094934
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
21 Jul 2014
-
Date of AGM
25 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
What products or services does Cyonics Cyto Solutions Private Limited offer?
Cyonics Cyto Solutions Private Limited offers a wide range of products and services, including Blood Collection Tubes, PRP Kit.
Who are the key members and board of directors at Cyonics Cyto Solutions?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srikanth Boga
|
Director | 21-Jul-2014 | Current |
|
Venkatakanthaiah Yerramalla
|
Director | 21-Jul-2014 | Current |
|
Shivanand Sindol
|
Director | 21-Jul-2014 | Current |
Financial Performance of Cyonics Cyto Solutions.
Cyonics Cyto Solutions Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 389.62% increase. The company also saw a substantial improvement in profitability, with a 129.11% increase in profit. The company's net worth moved up by a moderate rise of 7.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cyonics Cyto Solutions?
In 2023, Cyonics Cyto Solutions had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Capitis Micro Control Private LimitedSrikanth Boga is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cyonics Cyto Solutions?
Unlock and access historical data on people associated with Cyonics Cyto Solutions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cyonics Cyto Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cyonics Cyto Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.